Dainippon Sumitomo to buy Sepracor for $2.55bn
In a deal valued at about $2.55bn, Dainippon Sumitomo Pharma (DSP; Japan's seventh-largest drug company in terms of sales) agreed to pay $23 (a 26% premium) for each of US biotech Sepracor's 111mm outstanding shares.
- Chiral Chemistry
- Specialty Pharmaceuticals
- Full Acquisition
- Includes Contract
- Payment Includes Cash for Equity
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.